Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (1627 PAVIA CSA2016S, 1627 PAVIA CSA2016S)
Received: 13 April 2022
Accepted: 9 November 2022
First Online: 24 November 2022
: This study was conducted retrospectively from Pharmacovigilance report obtained for clinical purposes. Ethical approval was obtained from Eswatini Health and Human Research Review Board (EHHRRB) on January 26, 2021 with reference number of SHR274/2020.
: Not applicable.
: The authors have declared that no competing interests exist.